Drug Safety Board Adds Staffers With CDER Experience
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA appoints Toni Marie Nearing-Crowley and Lee Zwanziger as science policy analysts for Drug Safety Oversight Board.
You may also be interested in...
FDA Drug Safety Board Discusses Criteria For Releasing Emerging Safety Info
Board considers past actions regarding Shire’s Adderall and erectile dysfunction drugs in attempting to establish method for informing public of safety concerns.
NME Slowdown Shows Market Pressure On Me-Toos, Not FDA Caution – Lutter
DURHAM, N.C. - The decline in FDA's tally of new molecular entity approvals stems from fewer approvals of non-innovative products in recent years, while approvals of truly innovative products has largely held steady, according to FDA Deputy Commissioner for Policy, Planning and Preparedness Randall Lutter
Amgen Aranesp, Vectibix Setbacks Illustrate Risks Of Real World Trials
Amgen's failed Anemia of Cancer trial of Aranesp and Panitumumab Advanced Colorectal Cancer Evaluation (PACCE) trial of Vectibix may illustrate the potential pitfalls facing sponsors that conduct "real world" trials of their products